Reduced Intensity Versus Myeloablative Allogeneic Hematopoietic Cell Transplant for Myelofibrosis: A Single Institution Experience
Allogeneic hematopoietic cell transplant (alloHCT) is the only potentially curative therapy for myelofibrosis (MF). Outcomes after alloHCT for MF remain dismal, with 5-year overall survival (OS) of 30-40%. Given age, comorbidities, and often advanced disease, the decision of if and when to transplant can be a challenge. We undertook this analysis to investigate our institutional experience with alloHCT for MF.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Andrew D. Trunk, Yanwen Chen, Aaron T. Gerds, Betty K. Hamilton, Ronald M. Sobecks, Sudipto Mukherjee, Sophia R Balderman, Matt E. Kalaycio, Craig S Sauter, Claudio G. Brunstein Tags: 135 Source Type: research